RxDoctor Payments Data

Pornpimol Anprasertporn, MD

Neurology · Topeka, KSNPI 1265743462

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (38.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Amneal Pharmaceuticals LLC at 42.5% of the total. Reporting peaked in 2024 at $1,549 and has fallen 97.1% since, to $46 in 2025.

$3,802in general payments, 2019–2025

Across 42 payments — averaging $90.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$2K
  • Abbott$1K
  • Medtronic$429
  • Teva Pharmaceuticals USA, Inc.$234
  • Acadia Pharmaceuticals Inc$100
  • AbbVie$88

What the payments were for

  • Consulting fees$1,47139%
  • Travel & lodging$1,00426%
  • Food & beverage$1,25133%
  • Education$762%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,802 in reported general payments places this provider in the 70th percentile of 131 neurology providers in Kansas.

See all neurology providers in Kansas

Medicare billing

Part B allowed, 2024
$65,639
Medicare patients
188
Services billed
2,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine19$111,627
RytaryCarbidopa/Levodopa55$65,748
Carbidopa-LevodopaCarbidopa/Levodopa458$17,692
Carbidopa-Levodopa ErCarbidopa/Levodopa77$3,789
Ropinirole Hcl70$3,597
Primidone118$3,132
AmantadineAmantadine Hcl68$3,024
Entacapone16$2,308
Gabapentin86$2,232
Midodrine Hcl16$1,944
Propranolol Hcl93$1,935
Levetiracetam31$1,312
Pramipexole DihydrochloridePramipexole Di-Hcl40$1,210
Donepezil Hcl135$1,110
Memantine Hcl57$984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$234$111,62719 claims
Amneal Pharmaceuticals LLCRytary$1,616$65,74855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 131 neurology providers in Kansas.

Other neurology in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →